Track market-moving stories before they get noisy

BONITA SPRINGS, Fla.--(BUSINESS WIRE)--Herc Holdings Inc. (NYSE: HRI), one of North America's leading equipment rental suppliers operating through Herc Rentals Inc. (“Herc Holdings,” “Herc Rentals” or the “Company”), today announced that, as part of the Company's planned leadership succession, Aaron Birnbaum, currently president, will succeed Larry Silber as chief executive officer, effective Jan. 1, 2027. Birnbaum will also continue in his role as president and will join the Company's Board of.

 | Source: Daré Bioscience, Inc.

A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program

VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice President of Product Development of Daré Bioscience, will present on the Company’s Intelligent Drug Delivery System (DARE-IDDS) at the 16th annual Partnership Opportunities in Drug Delivery (PODD) conference, one of the leading drug delivery industry conferences, taking place October 29–30, 2026 in Boston, MA.

Ms. Proos will present “Expanding Chronic Therapy Adherence with a Single Programmable Device” on Friday, October 30, from 2:30 to 2:50 p.m. ET. The presentation will highlight the potential of DARE-IDDS to address challenges associated with long-term and chronic injection-based therapies by combining programmable drug delivery, wireless communication and dosing flexibility within a single subcutaneously implanted device.

Millions of patients on chronic therapies depend on repeated injections, frequent clinic visits and the discipline to stay on schedule. When patients miss doses, the benefits of even highly effective medicines can be lost. DARE-IDDS is designed to take that burden off the patient.

DARE-IDDS is a single device, implantable under the skin, that is designed to:

Store and deliver more than 100 discrete doses over periods ranging from months to yearsProgram each dose electronically, using independent drug reservoirs and electronic dose controlConnect wirelessly, with the potential to let patients and healthcare providers monitor and adjust treatment remotelyReduce treatment burden, potentially cutting the need for repeated injections, frequent clinic visits and ongoing medication management By combining extended drug storage with programmable delivery and patient control, DARE-IDDS is being developed to support a range of potential therapeutic applications. The technology is initially being targeted for contraception through Daré Bioscience’s DARE-LARC1 program, which is being developed with the goal of providing a long-acting, reversible contraceptive option designed to give women greater flexibility in managing their reproductive journey. Because DARE-IDDS is a platform, Daré Bioscience believes it may also have applications across other therapeutic areas where adherence, treatment burden and reliable dosing are significant issues, and where future development and commercial partners may see value.

“DARE-IDDS represents an opportunity to rethink how medications are delivered over the long term, particularly in therapeutic areas where adherence and treatment burden can limit the benefits of available therapies,” said Ms. Proos. “By bringing together programmable dosing, wireless connectivity and patient control in a single implantable device platform, we are working to advance a more flexible approach to drug delivery that has the potential to benefit patients, healthcare providers and future development and commercial partners.”

Daré Bioscience has collaborated with Cambridge Consultants, a global product development and technology consultancy, to advance the DARE-IDDS platform, combining drug delivery expertise with capabilities in implantable electronics, connectivity and device engineering. The collaboration reflects Daré Bioscience’s focus on advancing differentiated technology designed to address unmet needs and create new possibilities for patient-centered care.

DARE-IDDS is an investigational device in preclinical development. It has not been approved or cleared for clinical investigation in humans or for any use in humans. The DARE-IDDS features described in this press release are based on the results of technological proof-of-concept studies.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré Bioscience advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré Bioscience is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré Bioscience is working to change that. Learn more at darebioscience.com.

FORWARD-LOOKING STATEMENTS

Daré Bioscience cautions you that all statements, other than statements of historical facts, contained in this press release are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “prepare,” “progress,” “seek,” “should,” “would,” “build” or the negative version of these words and similar expressions.

In this press release, forward-looking statements include, but are not limited to, statements relating to: the potential capabilities of DARE-IDDS as part of a therapeutic product for humans, including storing and delivering more than 100 discrete doses over periods ranging from months to years, electronic dose programming, and wireless connectivity enabling remote treatment monitoring and adjustment; the potential of DARE-IDDS to improve treatment adherence and reduce treatment burden; the potential application of DARE-IDDS in a broad range of therapeutic areas; the therapeutic and market potential of future products utilizing DARE-IDDS; continued development of DARE-LARC1 and its potential to demonstrate safety and effectiveness as a long-acting reversible contraceptive product; and the potential for Daré Bioscience to enter into strategic collaborations for development and commercialization of therapeutic products utilizing DARE-IDDS.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Daré Bioscience’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: advancing DARE-LARC1 and any future product candidate utilizing DARE-IDDS through preclinical stage development and into human clinical trials; the ability of product candidates utilizing DARE-IDDS to demonstrate acceptable safety, tolerability and efficacy, including contraceptive effectiveness, in humans; the potential that product candidates utilizing DARE-IDDS may not demonstrate the dose capacity, duration of drug storage and delivery, or wireless connectivity and remote treatment monitoring and adjustment functionality anticipated based on technological proof-of-concept studies of DARE-IDDS; the risk that positive findings in technological proof-of-concept studies, other nonclinical studies and/or early clinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; delays, increased costs, or failure in completing necessary nonclinical and clinical studies of a product candidate, including due to unanticipated requirements for additional testing; potentially more complex, costly or lengthy development and approval requirements for drug-device combination product candidates; delays or failure to obtain U.S. Food and Drug Administration (FDA) or foreign regulatory approval for a product candidate; achieving anticipated treatment adherence or reduction in treatment burden benefits with any DARE-IDDS-based product, if approved; difficulties establishing and maintaining relationships with development and/or commercial collaborators; Daré Bioscience's dependence on third parties to conduct nonclinical and clinical studies and manufacture and supply clinical trial material and commercial product, and the performance and resource commitments of such third parties; difficulties in manufacturing drug product candidates and their components at the required quality, stability and scale for clinical trials and commercialization; Daré Bioscience's ability to obtain additional capital when and as needed to execute its business strategy and continue as a going concern; dependence on grants and other financial awards from governmental entities and a private foundation and the risk that such funding may be reduced, delayed, or terminated, or may be insufficient to advance a product candidate into or through a particular stage of development as anticipated; potential suspension and delisting of Daré Bioscience's common stock from The Nasdaq Capital Market; failure of any products, if approved, to gain market acceptance or obtain adequate coverage, pricing and reimbursement from third-party payors; the risk that developments by competitors make Daré Bioscience's products or product candidates less competitive or obsolete; Daré Bioscience's ability to retain its licensed rights to develop and commercialize a product or product candidate; Daré Bioscience's ability to satisfy the monetary obligations and other requirements in connection with its exclusive in-license agreements covering the critical patents and related intellectual property related to its products and product candidates; Daré Bioscience's ability to adequately protect or enforce its, or its licensor’s, intellectual property rights; the lack of patent protection for the active ingredients in certain of Daré Bioscience's product candidates, which could expose its products to competition from other formulations using the same active ingredients; product liability claims; governmental investigations or actions relating to Daré Bioscience's products or product candidates or the business activities of Daré Bioscience, its commercial collaborators or other third parties on which Daré Bioscience relies; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; the effects of macroeconomic conditions, geopolitical events, and major changes and disruptions in U.S. government policies and operations on Daré Bioscience's ability to raise additional capital or on Daré Bioscience's operations, financial results and condition, and ability to achieve current plans and objectives; and cybersecurity incidents or similar events that compromise Daré Bioscience's technology systems and/or significantly disrupt Daré Bioscience's business or those of third parties on which Daré Bioscience relies.

Daré Bioscience’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Daré Bioscience’s risks and uncertainties, you are encouraged to review its documents filed with the U.S. Securities and Exchange Commission (SEC), including Daré Bioscience’s recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Daré Bioscience undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Contact:
Daré Bioscience Investor Relations
[email protected]

Source: Daré Bioscience, Inc.

NEW ORLEANS, Oct. 26, 2026 /PRNewswire/ -- Entergy will report its third quarter 2026 financial results before the market opens Monday, Nov. 2. Drew Marsh, chair and chief executive officer, and Kimberly Fontan, executive vice president and chief financial officer, invite you to listen to a live webcast discussion of Entergy's quarterly business update and financial results at 10 a.m.

26.10.2026 15:40, AAPL, EQT, VZ, BAAAAPL, META, SPCX

Index Dow Jones +0,56 % na 52508,14 b., S&P 500 +0,60 % na 7669,33 b., Nasdaq Composite +0,61 % na 26114,85 b.

Verizon reportoval výsledky za 3Q, ve kterém zaznamenal nejvyšší přírůstek zákazníků mobilních služeb za posledních pět let, přičemž více než dvojnásobně překonal očekávání analytiků. Výsledky dle Bloombergu naznačují, že restrukturalizační plán generálního ředitele Dana Schulmana začíná přinášet pozitivní výsledky. Společnost reportovala výnosy 34,3 mld. USD, přičemž očekávání analytiků bylo 34,76 mld. USD. Očištěný zisk na akcii dosáhl 1,31 USD při očekávání 1,28 USD. Na úrovni očištěného zisku na akcii společnost navýšila svůj roční výhled z pásma 4,99 až 5,04 USD na 5,04 až 5,06 USD. Analytici čekali 5,02 USD.

Společnost Meta zahajuje souběžně veřejné nabídky akcií třídy A prostřednictvím forwardových smluv v objemu 22,5 mld. USD a povinně konvertibilních prioritních akcií v objemu 12,5 mld. USD. Prostředky plánuje využít především na rozvoj AI infrastruktury a další firemní účely. Společnosti Nvidia, AMD a Broadcom projevily dle agentury Bloomberg zájem nakoupit akcie až za 5 mld. USD. Meta navíc plánuje v roce 2027 spustit další program prodeje akcií třídy C bez hlasovacích práv v objemu až 60 mld. USD. Prioritní akcie budou automaticky převedeny na kmenové akcie v srpnu 2029.

SpaceX dle Bloombergu uzavřela se společností Apollo závaznou dohodu o budoucím uzavření finančního leasingu na grafické procesory (GPU) a související vybavení datových center v odhadovaném celkovém objemu plateb přibližně 40 mld. USD.

EQT Corporation se dohodla na převzetí společnosti Range Resources financovaném akciemi v hodnotě přibližně 12,8 mld. USD. Spojením má podle EQT vzniknout největší a jediný vertikálně integrovaný producent zemního plynu v USA.

Společnost Apple dnes představila novou generaci iPadu mini s OLED displejem, voděodolnou konstrukcí a výkonnějším čipem. Zahájila tím týden plánovaných produktových novinek.

Společnost Anthropic zveřejnila registrační dokumenty ohledně primární veřejné nabídky akcií (IPO), čímž se přibližuje tomu, že se stane první veřejně obchodovanou společností zaměřenou primárně na vývoj nejpokročilejších modelů umělé inteligence. Dle dokumentů dnes předložených Komisi pro cenné papíry a burzy (SEC) by se její akcie měly začít obchodovat na burze Nasdaq Global Select Market pod tickerem ANT.

Nejsilnější akcie S&P
Změna
Nejslabší akcie S&P
Změna

Comfort Systems USA
+6,6 %
Fair Isaac
-8,1 %

Tesla
+6,1 %
Reddit
-5,6%

Dow
+4,5 %
EQT
-3,5 %

Lumentum
+4,3 %
Robinhood
-3,2 %

Datadog
+4,2 %
Coinbase
-3,1 %

Zdroj: Bloomberg

Marek Chudoba
Fio banka, a.s.
Prohlášení

Did you buy APP securities between February 12, 2026 and August 5, 2026? Affected APP Investor Summary Who: AppLovin Corporation (NASDAQ: APP) What: Securities fraud class action lawsuit filed Class Period: February 12, 2026 through August 5, 2026 Deadline to Seek Lead Plaintiff Status: November 16, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's projected revenue growth from its AI products and self-service application Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options RADNOR, Pa.

MIAMI, Fla. & LONGVIEW, Texas--(BUSINESS WIRE)--Right Lane Industries ("RLI"), a private industrial holding company, today announced that it has completed the acquisition of Capacity Trucks and LayMor from Terex Corporation (NYSE: TEX). Both businesses are headquartered in Longview, Texas and will operate as standalone companies under RLI ownership. Financial terms of the transaction were not disclosed. The acquisition marks RLI's latest carve-out of a non-core division from a large public indus.

Griffon is a niche North American building products firm focused on garage doors and ceiling fans after a recent strategic refocus. I rate GFF a 'sell' due to overvaluation, cyclical end-market weakness, declining earnings expectations, and a low credit rating despite strong dividend growth. GFF's dividend safety is acceptable with a 14-year growth streak and low payout ratio, but leverage, declining FCF, and non-investment grade credit remain concerns.

SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Endeavor Bancorp (OTCQX: EDVR) (the “Company” or “Bancorp”), the holding company for Endeavor Bank (the “Bank”), today reported net income of $2.12 million, or $0.44 per diluted share, for the third quarter of 2026, compared to $1.89 million, or $0.40 per diluted share, for the second quarter of 2026, and $1.73 million, or $0.36 per diluted share, for the third quarter of 2025. All financial results are unaudited.

“Endeavor delivered another strong quarter, with record net income, continued improvement in operating efficiency and strong net interest income,” said Julie Glance, CFO. “Deposit growth and a lower loan-to-deposit ratio strengthened our liquidity and funding position, while non-performing loans declined from the prior quarter and capital levels remained strong. These results position us well as we continue investing in our clients, team and long-term growth.”

Results for the third quarter of 2026 included a $525,000 provision for credit losses, reflecting continued prudent credit risk management. This compared to a $651,000 provision for credit losses in the second quarter of 2026, and a $396,000 provision for credit losses in the third quarter of 2025. Core pre-tax earnings, excluding taxes and loan loss provisions, were $3.54 million in the third quarter of 2026, an increase of $240,000, or 7.3%, compared to $3.30 million in the preceding quarter, and up $687,000, or 24.0%, from $2.86 million in the third quarter of 2025.

Income Statement
Higher interest income and disciplined funding costs drove improved earnings for the third quarter of 2026. Total interest income on loans and bank deposits and investments was $12.9 million, an increase of $525,000, or 4.2%, compared to the $12.4 million earned in the preceding quarter, while total interest expenses increased modestly by $53,000 during the same timeframe. Net interest income was $9.1 million in the third quarter of 2026, which was a 5.5% increase compared to the preceding quarter and a 17.9% increase compared to the third quarter of 2025.

The Company’s net interest margin was 4.41% in the third quarter of 2026, unchanged from the prior quarter and a 32 basis point increase compared to 4.09% in the third quarter of 2025. The yield on total earning assets during the third quarter of 2026 was 6.30%, compared to 6.37% in the preceding quarter, and 6.47% in the third quarter of 2025. The cost of funds decreased to 2.04% in the third quarter, compared to 2.12% in the second quarter of 2026, and decreased compared to 2.53% in the third quarter of 2025.

“Our net interest margin remained stable in the third quarter and expanded 32 basis points year-over-year,” said Dan Yates, CEO. “Disciplined balance sheet management supported a 4.41% net interest margin, reflecting our continued emphasis on long-term stability.”

Non-interest income was $298,000 in the third quarter of 2026, a decrease of $59,000 or 16.5% compared to the second quarter of 2026, and a decrease of $103,000, or 26.0% compared to the third quarter of 2025.

Non-interest expense was $5.8 million in the third quarter of 2026, an increase of $174,000 compared to the second quarter of 2026, and an increase of $584,000 compared to the third quarter of 2025. Operating efficiency continued to improve, with the efficiency ratio declining to 62.1%, compared with 63.2% in the second quarter and 64.7% in the third quarter of 2025.

The Company’s annualized return on average equity for the third quarter of 2026 was 12.28% an increase compared to the second quarter of 2026 at 11.40% and decreased compared to 13.58% in the third quarter of 2025. The annualized return on average assets for the third quarter of 2026 was 1.01% compared to the preceding quarter at 0.95%, and increased compared to 0.90% for the third quarter of 2025.

Balance Sheet
Total assets increased by $11.9 million, or 1.5%, during the third quarter of 2026 to $835.0 million at September 30, 2026, compared to $823.0 million at June 30, 2026, and increased $74.7 million, or 9.8%, compared to September 30, 2025. Balance sheet liquidity remains strong with cash balances of $147.8 million, which represents 17.7% of total assets as of September 30, 2026. The Company’s investment securities increased $1.3 million during the third quarter of 2026 to $36.4 million as of September 30, 2026, representing 4.4% of total assets. Total available borrowing capacity through the Federal Home Loan Bank and the Federal Reserve discount window totaled $231.2 million as of September 30, 2026.

Total loans outstanding decreased $19.9 million, or 3.0%, during the quarter to $644.9 million at September 30, 2026, compared to $664.8 million three months earlier, and increased $12.3 million, or 1.9% when compared to $632.6 million a year earlier. Payoffs of $47.6 million, as clients completed, sold or refinanced their projects, exceeded the new loan production of $28.5 million, which was led by our core C&I and CRE lending.

“Many of the loans that paid off were seasoned, lower yielding credits, creating an opportunity to redeploy capital into new lending at current market rates, a shift we expect to benefit net interest margin over time. Our deposit based also continued to expand, providing a reliable source of funding as loan demand increases,” said Steve Sefton, President.

“Our record quarterly earnings demonstrate the continued strength of Endeavor’s business model and our team’s focus on disciplined execution. While loan payoffs exceeded new production during the quarter, our growing deposit base, strong liquidity and capital position provide a solid foundation to support future growth. We remain focused on expanding relationships with Southern California businesses through our differentiated consultative banking approach,” said Yates.

Endeavor recently added Carlos Donis, SVP Orange County Team Leader & Relationship Manager, to lead the Bank’s expansion into Orange County.

Total non-performing loans decreased to 0.36% of the total loans as of September 30, 2026, compared to 0.45% as of June 30, 2026. Net charge-offs totaled $826,000 during the third quarter of 2026, compared with net loan recoveries of $52,000 in the second quarter of 2026 and net loan recoveries of $8,000 in the third quarter of 2025.

The provision for credit losses was $525,000 in the third quarter of 2026, compared to $651,000 in the second quarter of 2026, and $396,000 in the third quarter of 2025. The total allowance for credit losses balance decreased to $10.6 million, or 1.65% of total loans, at September 30, 2026 compared to $10.9 million at June 30, 2026.

Total deposits increased by $6.2 million, or 0.9%, during the third quarter of 2026 to $731.2 million at September 30, 2026, compared to $725.0 million three months earlier, and increased $52.9 million, or 7.8%, when compared to $678.3 million a year earlier. Excluding wholesale deposits, which declined during the quarter, core relationship deposits grew approximately $18.4 million, or 2.6%, with noninterest-bearing deposits at $272 million, or 37.2% of total deposits, compared to $265.0 million at June 30, 2026. The loan to deposit ratio was 88.2% at September 30, 2026, compared to 91.7% at June 30, 2026, and 93.3% as of September 30, 2025. “Prudent deposit base management, supported by strong customer relationships, increased total deposits and strengthened our funding position during the third quarter of 2026,” said Glance. “This growth in core deposits over the preceding quarter and year-over-year provides a stable, cost-effective source of funding as we continue to support our customer’s needs.”

As a participant in reciprocal deposit placement networks, the Bank offers customers access to FDIC insurance coverage on deposit balances in excess of the standard $250,000 limit while maintaining the customer relationship at the Bank. The Company continues to utilize a conservative level of wholesale funding, wholesale deposits totaled $31.8 million, representing 4.2% of total deposits at September 30, 2026, compared to $44.7 million, or 6.2% of total deposits, at June 30, 2026. At September 30, 2025, wholesale deposits totaled $44.6 million, or 6.6%.

Shareholders’ equity increased to $68.2 million at September 30, 2026, compared to $66.6 million at June 30, 2026, and $51.0 million at September 30, 2025. Tangible book value per share increased to $15.46 at September 30, 2026, compared to $15.11 three months earlier and $14.21 one year earlier.

Capital
The Bank’s Tier 1 leverage ratio was 11.54% as of September 30, 2026, compared to 11.82% as of June 30, 2026. The Tier 1 risk-based capital ratio was 12.08% as of September 30, 2026, compared to 11.76% as of June 30, 2026, and increased from 10.32% as of September 30, 2025. The total risk-based capital ratio was 13.33% as of September 30, 2026, and 13.02% as of June 30, 2026. All capital ratios remained well above regulatory minimums for the third quarter of 2026.

About Endeavor Bancorp
Endeavor Bancorp, the holding company for Endeavor Bank, is primarily owned and operated by Southern Californians for Southern California businesses and their owners. The bank’s focus is local: local decision-making, local board, local founders, local owners, and relationships with local clients in Southern California.

Headquartered in downtown San Diego in the Symphony Towers building, the Bank also operates a loan production and executive administration office in Carlsbad, a branch office in La Mesa, and a loan production office in Riverside. In addition, the Bank maintains production teams throughout Southern California. Endeavor Bank provides traditional business banking services across a broad spectrum of industries and specialties. Unique to the bank is its consultative banking approach that partners our business clients with Endeavor Bank’s senior management. Together, we build strategies and provide resources that solve problems, plan for the future, and help clients’ efforts to grow revenues and profits. Endeavor Bancorp trades on the OTCQX® Best Market under the symbol “EDVR.” Visit www.endeavor.bank for more information.

Endeavor Bank is rated by Bauer Financial as Five-Star “Superior” for strong financial performance, the top rating given by the independent bank rating firm. DepositAccounts.com awarded Endeavor Bank an A rating.

EDVR Shareholders
With many of our shareholders transferring their EDVR shares to their brokerage companies, along with ongoing trading taking place, Bancorp may not have the most current shareholder contact information. If you are an EDVR shareholder and would like to receive information via a more timely method, please complete the Shareholder Communication Preference Form on our website: https://www.bankendeavor.com/investor-relations so we can keep you updated on EDVR news, and invite you to various shareholder networking events throughout the year. 

Forward-Looking Statements
This press release includes “forward-looking statements,” as such term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current beliefs of the Company’s directors and executive officers (collectively, “Management”), as well as assumptions made by and information currently available to the Company’s Management. All statements regarding the Company’s business strategy and plans and objectives of Management of the Company for future operations, are forward-looking statements. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect” and “intend” and words or phrases of similar meaning, as they relate to the Company or the Company’s Management, are intended to identify forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s expectations (“cautionary statements”) are loan losses, rapid and unanticipated deposit withdrawals, unavailability of sources of liquidity, additional regulatory requirements that may be imposed on community banks or banks generally, changes in interest rates, loss of key personnel, lower lending limits and capital than competitors, regulatory restrictions and oversight of the Company, the secure and effective implementation of technology, risks related to the local and national economy, the effect on customers, changes in real estate values, the Company’s implementation of its business plans and management of growth, loan performance, interest rates, and regulatory matters, the effects of trade, monetary and fiscal policies, inflation, and changes in accounting policies and practices. Based upon changing conditions, if any one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, actual results may vary materially from those described as anticipated, believed, estimated, expected, or intended. The Company does not intend to update these forward-looking statements.

SELECTED FINANCIAL DATA
(In thousands of dollars, except for ratios and per share amounts)
Unaudited
         
September 30, 2026 June 30, 2026 September 30, 2025  
(Consolidated) (Consolidated) (Consolidated)SUMMARY OF OPERATIONS      Interest income $12,942  $12,417  $12,169 Interest expense  3,887   3,834   4,487 Net interest income  9,055   8,583   7,682 Provision for credit losses  525   651   396 Net interest income after loss provision  8,530   7,932   7,286 Non-interest income  298   357   401 Non-interest expense  5,809   5,635   5,225 Income before tax  3,019   2,653   2,461 Federal income tax expense  572   488   467 State income tax expense  331   280   269 Net income $2,116  $1,885  $1,725        Core pretax earnings* $3,544  $3,304  $2,857 *excludes taxes and provision for loan losses             PER COMMON SHARE DATA      Number of shares outstanding (000s)*  4,411   4,410   3,587 *Adjusted for May 2026 Stock Dividend      Earnings per share, basic $0.48  $0.43  $0.42 Earnings per share, diluted $0.44  $0.40  $0.36 Book Value per share $15.46  $15.11  $14.21        BALANCE SHEET DATA      Assets $834,962  $823,048  $760,213 Investments securities  36,406   35,103   31,557 Total loans, net of unearned income  644,921   664,829   632,573 Allowance for Credit Losses  10,646   10,919   8,912 Total deposits  731,196   724,988   678,300 Borrowings  26,868   26,844   26,770 Shareholders’ equity  68,187   66,649   50,979 Loan to Deposit ratio  88.20%  91.70%  93.26%Wholesale Deposits to Total Deposits  4.20%  6.17%  6.57%       AVERAGE BALANCE SHEET DATA      Average assets $827,009  $794,589  $758,125 Average total loans, net of unearned income  648,874   659,737   620,851 Average total deposits  726,146   696,483   676,209 Average shareholders' equity  68,341   66,358   50,420        ASSET QUALITY RATIOS      Net (charge-offs) recoveries $826  $(52) $(8)Net (charge-offs) recoveries to average loans  0.13%  -0.01%  -0.01%Non-performing loans as a % of loans  0.36%  0.45%  0.21%Non-performing assets as a % of assets  0.28%  0.37%  0.17%Allowance for loan losses as a % of total loans  1.65%  1.64%  1.41%Non-performing assets as a % of allowance for loan losses  22.07%  27.58%  14.87%       FINANCIAL RATIOS\STATISTICS      Annualized return on average equity  12.28%  11.40%  13.58%Annualized return on average assets  1.01%  0.95%  0.90%Net interest margin  4.41%  4.41%  4.09%Efficiency ratio  62.10%  63.19%  64.65%       CAPITAL RATIOS      Tier 1 leverage ratio -- Bank  11.54%  11.82%  10.15%Common equity tier 1 ratio -- Bank  12.08%  11.76%  10.32%Tier 1 risk-based capital ratio -- Bank  12.08%  11.76%  10.32%Total risk-based capital ratio -- Bank  13.33%  13.02%  11.54%       TCE/TA *  8.17%  8.10%  6.71%Tangible Book Value per Share $15.46  $15.11  $14.21        *Non-GAAP financial measure.      Unaudited financials 2026              Endeavor Bancorp Contact Information:
(858) 230.5185
Dan Yates, CEO
[email protected]

(858) 230.4243
Steve Sefton, President
[email protected]

Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I'll be watching whether CASGEVY and JOURNAVX stay on pace for management's $500 million non-CF revenue target.

New platform connects domain experts with mission-critical AI work as companies compete for the human expertise needed to move AI from innovation to execution  | Source: EXL

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- iMerit, an EXL company, today announced the launch of its iMerit Scholars platform, designed to seamlessly manage hundreds of thousands of global domain experts (Scholars) who work on fine-tuning, evaluation and validation of generative AI models. This represents the first major launch since EXL (Nasdaq: EXLS) acquired iMerit in July to accelerate the progression of frontier AI into regulated enterprises.

The launch comes as the AI talent war heats up across generative and physical AI. The iMerit Scholars program already brings together a curated global community of 30,000 domain experts and linguists to support advanced model training, evaluation, validation and safety across specialized fields. The new iMerit Scholars platform provides a unified system to recruit, onboard, curate, assign, manage, engage, pay, and retain these experts at scale. It is powered by iMerit’s proprietary Ango Hub, which allows customers and experts to collaborate on complex multimodal data to generate highly curated and validated training artifacts for high-stakes models. 

“iMerit has always differentiated itself by a curated, people-first approach. We’re seeing that become even more important as we scale up to help the frontier labs,” said Radha Basu, executive vice president, head of iMerit at EXL. “The next phase of the GenAI race is about creating a painless and supportive infrastructure so that these highly capable specialists can enjoy their work and give their best. Scaling high quality and high engagement is mainly a human capital opportunity, backed by enabling technology. The iMerit Scholars platform is designed to create a seamless experience for top-notch talent to continue building and improving the next generation of AI.”

“Now, as a part of EXL, we are expanding from the creation of models in frontier labs to the implementation of model workflows in highly regulated enterprises in banking, healthcare and insurance. Once again, we find that trust, safety, and last-mile customization will dictate the success of AI projects in these sectors. We need people who are knowledgeable enough not just to teach models, but to prove them wrong and correct them. That parallel human authority is what will help move AI from innovation to trusted execution,” added Basu.

Leveraging Trolley’s global payouts platform, iMerit Scholars incorporates compliance and global secure payments to create a mutually beneficial environment for customers and experts. 

The iMerit Scholars program was built to meet the need for structured reasoning, domain nuance, and ongoing evaluation across high-stakes use cases in healthcare, physical AI, finance, and foundation models. The iMerit Scholars community brings together over 30,000 invited and vetted professionals from 118 countries representing 106 languages across fields such as medicine, mathematics, agriculture, linguistics, and autonomous systems. iMerit works with them to test, challenge, and “torment” models, helping improve performance in real-world conditions through techniques like RLHF, red-teaming, Q&A prompting, chain-of-thought tracing, and evaluation.

The iMerit Scholars platform matches experts with projects aligned to their specialization, enabling more consistent engagement and higher-quality outcomes. iMerit Scholars platform also introduces new capabilities to support this evolving workforce model, including:

Expert matching based on domain specialization and cognitive skill setsSecure, compliant workflows for sensitive data environmentsGlobal payments and workforce infrastructure through TrolleyIntegrated tooling for training, evaluation, and model feedback loops For experts, iMerit Scholars platform represents a move from fragmented experiences to a meaningful, ongoing relationship.

“Working with AI in this way feels like contributing to something foundational,” said Pavel Kopach, M.D. Department of Pathology, Beth Israel Deaconess Medical Center, and iMerit Scholar in Healthcare AI. “You’re not just labeling data, you’re helping shape how these systems reason and behave in your field. That’s both challenging and incredibly rewarding.”

To learn more about iMerit, an EXL company, visit iMerit.ai.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL harnesses the power of data, AI, and deep industry knowledge to transform businesses, including the world's leading corporations in industries including insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 68,000 employees spanning six continents. For more information, visit www.exlservice.com.

Media Contact: [email protected] 

NOVATO, Calif.--(BUSINESS WIRE)--BANK OF MARIN BANCORP REPORTS THIRD QUARTER FINANCIAL RESULTS DRIVEN BY LOAN GROWTH, NIM EXPANSION AND HIGHER EARNINGS.

RESTON, Va., Oct. 26, 2026 /PRNewswire/ -- CACI International Inc (NYSE: CACI) announced today that it has been awarded a five-year task order valued at up to $281 million by the U.S. Navy's Naval Surface Warfare Center (NSWC) Crane to support in strengthening and advancing next-generation electromagnetic warfare capabilities across the Department of War (DoW).

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about IonQ, Inc. (IONQ - Free Report) .

IonQ currently has an average brokerage recommendation (ABR) of 1.50, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 14 brokerage firms. An ABR of 1.50 approximates between Strong Buy and Buy.

Of the 14 recommendations that derive the current ABR, 10 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.4% and 7.1% of all recommendations.

Brokerage Recommendation Trends for IONQ

Check price target & stock forecast for IonQ here>>>

While the ABR calls for buying IonQ, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Should You Invest in IONQ?In terms of earnings estimate revisions for IonQ, the Zacks Consensus Estimate for the current year has declined 40.3% over the past month to -$1.26.

Analysts' growing pessimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates lower, could be a legitimate reason for the stock to plunge in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for IonQ. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Therefore, it could be wise to take the Buy-equivalent ABR for IonQ with a grain of salt.

Shell and its partners have decided to double the export capacity of a Canadian LNG facility. Energy Transfer's pipelines help to move natural gas, and its business model sidesteps commodity risk.

The company's largest investment in food to date will enhance the most popular menu items across 15 resorts New experiences include the Vail Ice Bar, Park City Mountain's S'mores Sleigh, Whistler Blackcomb's Caviar and Champagne service and Breckenridge's Climb and Dine series Elevating mountain food is central to Vail Resorts' Epic Experience commitment to deliver the best and most differentiated guest experience in skiing and riding Epic Pass Holders save 20% on dining all season; Pass prices increase after November 15 BROOMFIELD, Colo., Oct. 26, 2026 /PRNewswire/ -- As first flakes fall across the mountains and excitement builds for what many hope will be an exceptional Super El Niño snow season, Vail Resorts is giving guests more reason to savor their time on the slopes with new culinary and après experiences.

Plus, the AI bet faces a new earnings test this week

Bank of Hawaii (BOH - Free Report) reported $200.11 million in revenue for the quarter ended September 2026, representing a year-over-year increase of 9.6%. EPS of $1.49 for the same period compares to $1.20 a year ago.

The reported revenue represents a surprise of -1.51% over the Zacks Consensus Estimate of $203.16 million. With the consensus EPS estimate being $1.52, the EPS surprise was -1.97%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Bank of Hawaii performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Loans and Leases Charged-Off to Average Loans and Leases Outstanding (annualized): 0.1% versus 0.1% estimated by four analysts on average.Net Interest Margin: 2.8% versus the four-analyst average estimate of 2.8%.Efficiency Ratio: 56.5% versus the four-analyst average estimate of 55.8%.Average Balance - Total earning assets: $22.24 billion compared to the $22.25 billion average estimate based on three analysts.Total Non-Performing Assets: $43.41 million versus the three-analyst average estimate of $13.61 million.Total Non-Accrual Loans and Leases: $43.24 million compared to the $13.33 million average estimate based on three analysts.Tier 1 Capital Ratio: 14.4% compared to the 14.6% average estimate based on two analysts.Tier 1 Leverage Ratio: 8.8% versus 8.9% estimated by two analysts on average.Total Capital Ratio: 15.4% compared to the 15.7% average estimate based on two analysts.Service Charges on Deposit Accounts: $9.05 million versus $8.52 million estimated by four analysts on average.Mortgage Banking: $0.91 million compared to the $0.86 million average estimate based on four analysts.Net Interest Income (FTE): $157.4 million versus $159.5 million estimated by four analysts on average.View all Key Company Metrics for Bank of Hawaii here>>>

Shares of Bank of Hawaii have returned -1.5% over the past month versus the Zacks S&P 500 composite's -1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Key Takeaways AI-driven vulnerabilities are accelerating cyber threats, boosting attention on cybersecurity firms.Cybersecurity ETFs delivered strong year-to-date gains, reflecting heightened investor attention.ETFs including IHAK offer exposure to cybersecurity firms, with annual gains ranging from 48.5% to 63.9%. A wave of artificial intelligence (AI)-discovered vulnerabilities emerged last week in PHP, the programming language powering nearly 70% of the web, prompting industry experts to label the development as “Black October.” Cybersecurity teams worldwide are scrambling to patch critical flaws found using advanced AI models, with some executives noting that attacks observed over just two days could rank among the most severe security breaches of an entire year.

As one can expect, the disclosure rattled governments, banks, and tech giants alike, and Wall Street responded swiftly. Shares of major security providers, including Okta (OKTA - Free Report) , Palo Alto (PANW - Free Report) and CrowdStrike (CRWD - Free Report) , rallied sharply last week as investors bet that the chaos would accelerate corporate spending on defensive infrastructure. 

This heightened investor attention has brought cybersecurity exchange-traded funds (ETFs) into a bright spotlight, as these funds provide diversified exposure to companies positioned to address the growing cybersecurity threats.

For investors, this episode underscores how the rapid expansion of AI is not only benefiting core AI accelerators like NVIDIA (NVDA - Free Report) but also creating long-term growth opportunities for the cybersecurity industry, thereby bringing cybersecurity-focused exchange-traded funds (ETFs) into focus.

Before diving deep into the specifics of these ETFs, we must dig deeper into how AI’s explosive growth is influencing the cybersecurity industry, what role these firms play in connection to AI’s vulnerabilities, and how investors should reassess their portfolio positions around these security-focused funds.

How Is AI Reshaping the Cyber Threat Landscape?The PHP episode illustrates a fundamental shift: AI is compressing the attack lifecycle. According to the European Union Agency for Cybersecurity, the gap between vulnerability discovery and exploitation has shrunk from years to months, and in some cases to minutes. 

To this end, it is imperative to mention that, as per a report from the World Economic Forum (“WEF”), published in May 2026, 94% of cyber leaders now identify AI as the defining force in cybersecurity, with 77% of organizations already using it in cyber operations. 

The firms within cybersecurity ETFs are precisely the vendors building the automated defenses that enterprises are deploying to prevent cyberattacks. 

For instance, Palo Alto Networks offers Unit 42 Continuous Frontier AI Defense, an always-on agentic service that uses frontier models to discover and validate exploitable vulnerabilities before attackers can exploit them. The company also offers Prisma AIRS to secure enterprise AI applications and agents. 

CrowdStrike’s Falcon platform unifies endpoint, identity, cloud, and AI protection in one AI-native system, with Charlotte AI agents that triage detections and accelerate response at machine speed. Cloudflare leverages its global network — processing trillions of requests daily — to correlate live traffic with code vulnerabilities and deploy edge protections before patches are written. 

The payoff from these tools is measurable, not theoretical: organizations that extensively leverage AI in security reduce average breach costs by up to $1.9 million and shorten breach lifecycles by roughly 80 days, according to the WEF report.

In short, the same technology that creates the vulnerability is also used as the most potent remedy, and the companies selling that remedy are among the top holdings of prominent cybersecurity ETFs.  

Cybersecurity ETFs in Spotlight For investors, the “Black October” moment once again challenges the assumption that cybersecurity is merely a defensive, slow-growth allocation. The sector has already delivered strong returns this year, with major sector indices like the Nasdaq CTA Cybersecurity Index surging a solid 50.5% year to date. 

Considering the aforementioned discussion, the recent developments in AI vulnerabilities put the spotlight on the following cybersecurity ETFs:

First Trust NASDAQ Cybersecurity ETF (CIBR - Free Report)

This fund, with net assets worth $18.36 billion, offers exposure to 45 companies primarily involved in the building, implementation, and management of security protocols applied to private and public networks, computers, and mobile devices to provide protection of the integrity of data and network operations. CRWD, Fortinet (FTNT - Free Report) and PANW hold the first three spots in the fund, carrying 8.40%, 7.93% and 7.50% weight, respectively. 

CIBR has surged 48.5% year to date and charges 58 basis points (bps) in fees. It traded at a good volume of 3.18 million shares in the last trading session.

Amplify Cybersecurity ETF (HACK - Free Report)

This fund, with net assets worth $3.63 billion, tracks 23 companies actively involved in providing cybersecurity solutions that include hardware, software, and services. CRWD, Broadcom and Cisco Systems hold the first three spots in the fund, carrying 5.77%, 5.76% and 5.38% weight, respectively. 

HACK has gained 59.1% year to date and charges 60 bps in fees. It traded at a volume of 0.53 million shares in the last trading session.

Global X Cybersecurity ETF (BUG - Free Report)

This fund, with net assets worth $2.23 billion, includes 30 companies that stand to potentially benefit from the increased adoption of cybersecurity technology, such as those whose principal business lies in the development and management of security protocols preventing intrusion and attacks to systems, networks, applications, computers and mobile devices. OKTA, CRWD and FTNT hold the first three spots in the fund, carrying 9.37%, 7.48% and 6.91% weight, respectively. 

BUG has surged 63.9% year to date and charges 50 bps in fees. It traded at a good volume of 2.46 million shares in the last trading session.

iShares Cybersecurity and Tech ETF (IHAK - Free Report)

This fund, with net assets worth $1.27 billion, offers exposure to 34 firms involved in cybersecurity hardware, software & services. Netspoke, Qualys and Zscaler hold the first three spots in the fund, carrying 6.84%, 6.15% and 6.09% weight, respectively. 

IHAK has surged 53.7% year to date and charges 47 bps in fees. It traded at a volume of 0.36 million shares in the last trading session.

Comcast (CMCSA - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this cable provider have returned +3.6%, compared to the Zacks S&P 500 composite's -1.2% change. During this period, the Zacks Cable Television industry, which Comcast falls in, has gained 0.7%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Comcast is expected to post earnings of $0.67 per share for the current quarter, representing a year-over-year change of -20.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -5.2%.

The consensus earnings estimate of $3.52 for the current fiscal year indicates a year-over-year change of -18.3%. This estimate has changed +0.6% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $3.57 indicates a change of +1.5% from what Comcast is expected to report a year ago. Over the past month, the estimate has changed -1.7%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for Comcast.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Comcast, the consensus sales estimate of $30.18 billion for the current quarter points to a year-over-year change of -6.6%. The $120.07 billion and $117.03 billion estimates for the current and next fiscal years indicate changes of -2.9% and -2.5%, respectively.

Last Reported Results and Surprise HistoryComcast reported revenues of $29.3 billion in the last reported quarter, representing a year-over-year change of -6.1%. EPS of $1.07 for the same period compares with $1.12 a year ago.

Compared to the Zacks Consensus Estimate of $29.35 billion, the reported revenues represent a surprise of -0.18%. The EPS surprise was +9.18%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Comcast is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Comcast. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

NEW YORK--(BUSINESS WIRE)--TOMS Capital Investment Management (“TCIM”), which manages funds that together have an investment representing an approximately 4.65% economic interest in Voya Financial, Inc. (NYSE: VOYA) (“Voya” or the “Company”), has filed definitive proxy materials to provide shareholders the opportunity to consider and vote on a non-binding resolution. This non-binding resolution allows shareholders to convey unequivocally that they “no longer continue to have confidence in the b.

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

We know earnings results are vital, but how a company performs compared to bottom line expectations can be even more important when it comes to stock prices, especially in the near-term. This means that investors might want to take advantage of these earnings surprises.

Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.

The Zacks Earnings ESP, ExplainedThe Zacks Expected Surprise Prediction, or ESP, works by locking in on the most up-to-date analyst earnings revisions because they can be more accurate than estimates from weeks or even months before the actual release date. The thinking is pretty straightforward: analysts who provide earnings estimates closer to the report are likely to have more information.

Now that we understand the basic idea, let's look at how the Expected Surprise Prediction works. The ESP is calculated by comparing the Most Accurate Estimate to the Zacks Consensus Estimate, with the percentage difference between the two giving us the Zacks ESP figure.

Bringing together a positive earnings ESP alongside a Zacks Rank #3 (Hold) or better has helped stocks report a positive earnings surprise 70% of the time. Furthermore, by using these parameters, investors have seen 28.3% annual returns on average, according to our 10 year backtest.

Most stocks, about 60%, fall into the #3 (Hold) category, and they are expected to perform in-line with the broader market. Stocks with a #2 (Buy) and #1 (Strong Buy) rating, or the top 15% and top 5% of stocks, respectively, should outperform the market, with Strong Buy stocks outperforming more than any other rank.

Should You Consider Baker Hughes?The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Baker Hughes (BKR - Free Report) holds a #1 (Strong Buy) at the moment and its Most Accurate Estimate comes in at $0.65 a share one day away from its upcoming earnings release on October 27, 2026.

BKR has an Earnings ESP figure of +2.08%, which, as explained above, is calculated by taking the percentage difference between the $0.65 Most Accurate Estimate and the Zacks Consensus Estimate of $0.64. Baker Hughes is one of a large database of stocks with positive ESPs. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

BKR is one of just a large database of Oils and Energy stocks with positive ESPs. Another solid-looking stock is Valero Energy (VLO - Free Report) .

Valero Energy is a Zacks Rank #1 (Strong Buy) stock, and is getting ready to report earnings on February 4, 2027. VLO's Most Accurate Estimate sits at $17.04 a share 101 days from its next earnings release.

For Valero Energy, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $15.58 is +9.35%.

Because both stocks hold a positive Earnings ESP, BKR and VLO could potentially post earnings beats in their next reports.

Find Stocks to Buy or Sell Before They're ReportedUse the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>

Vůbec poprvé v historii čínské automobilky prodaly v Evropě za celé jedno čtvrtletí více vozů než jejich japonští konkurenti. Historický milník jen podtrhuje skutečnost, že čínské značky jako BYD nebo Chery si na evropském trhu budují čím dál silnější pozici.

Podle dat společnosti Dataforce se registrace vozů čínských značek v září meziročně zhruba zdvojnásobily a představovaly 12,7 procenta všech prodejů v Evropě, především díky hybridním modelům. Tím předstihly japonské výrobce včetně Toyoty, jejichž podíl činil 11,9 procenta, informuje agentura Bloomberg.

Evropskému trhu sice nadále odminují domácí hráči jako třeba Volkswagen či Renault, nicméně rychlost nástupu čínských výrobců je překvapivá. Ještě před pěti lety totiž čínské značky tvořily sotva jedno procento evropských prodejů. Naproti tomu japonští výrobci si své postavení budovali v Evropě desítky let.

Toyota prodává vozy v Evropě již od roku 1963 a dnes provozuje továrny napříč kontinentem. Nissan zase vyrábí automobily ve svém závodě v britském Sunderlandu od roku 1986. Čínské značky slaví mimořádný úspěch zejména ve Velké Británii, kde se SUV Jaecoo 7 od společnosti Chery stalo nejprodávanějším modelem v březnu i září.

Tento posun představuje pro evropské automobilky dvojitou ránu, protože kromě ukrojování podílu na domácím trhu se jim nedaří právě ani v Číně, kde tamní zákazníci začínají před Volkswagenem či BMW dávat přednost domácím výrobcům, kteří uvádějí nové modely rychleji a za nižší ceny. Současně slábnoucí poptávka v Číně nutí firmy jako BYD hledat nové odbytiště v zahraničí.

Začátkem října představily společnosti Chery, BYD a značka Zeekr ze skupiny Geely na autosalonu v Paříži řadu nových modelů. Mezi nimi byl například BYD Dolphin G DM-i, kompaktní plug-in hybrid vyvinutý speciálně pro evropský trh. Rozšiřování nabídky elektromobilů navíc čínským výrobcům umožňuje těžit z rostoucí poptávky po úspornějších vozech v době rekordně vysokých cen pohonných hmot.

Evropská unie se snaží expanzi čínských výrobců, která je podle Bruselu částečně podporována státními subvencemi, zpomalit. Po zavedení dodatečných cel na elektromobily vyrobené v Číně se tento měsíc členské státy předběžně dohodly také na omezení rychle rostoucího dovozu hybridních vozů z Číny. Spekulace o dalších opatřeních ale vedly k tomu, že dovoz hybridů do Evropy dále zrychlil.

EU zároveň zvažuje nová pravidla, která by při poskytování dotací a dalších pobídek zvýhodňovala automobily vyráběné přímo v Evropě. Návrhy počítají například s navázáním některých daňových úlev pro firemní vozy na evropskou výrobu, což by mohlo mít významný dopad zejména v zemích, jako je Německo, kde velkou část trhu tvoří firemní a flotiloví zákazníci.

Čínští výrobci se na možná omezení připravují přesunem části výroby přímo do Evropy. Chery chystá výrobu v Barceloně, BYD dokončuje svůj závod v Maďarsku a Leapmotor už vyrábí model B10 SUV v továrně koncernu Stellantis ve španělské Zaragoze v rámci společného podniku obou firem.

Key Takeaways EPD's Q3'26 EPS is expected to rise 21.3% to 74 cents, with revenues projected to grow 27.7% to $13.40B. EPD's NGL and crude oil pipeline margins are expected to reach $1.57 billion & $420 million, respectively.EPD's fee-based contracts may support cash flows despite expected weakness in natural gas pipelines. Enterprise Products Partners L.P. (EPD - Free Report) is set to report third-quarter 2026 results on Oct. 29, before the opening bell.

In the last reported quarter, the partnership’s adjusted earnings of 84 cents per share beat the Zacks Consensus Estimate of 75 cents due to increased international demand, higher marketing margins and record system activity.

The partnership’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters and missed it twice, delivering an average surprise of 1.5%. This is depicted in the graph below.

Estimate Trend for EPDThe Zacks Consensus Estimate for third-quarter earnings per share (EPS) of 74 cents has seen no upward or downward revisions in the past seven days. The estimated figure indicates a 21.3% improvement from the prior-year reported figure.

The Zacks Consensus Estimate for revenues of $13.35 billion implies a 27.7% increase from the year-ago recorded figure.

Factors to Consider for EPD's Q3 ResultsEnterprise Products is a leading player in the midstream energy sector, with an extensive pipeline network spanning more than 50,000 miles, liquids storage facilities with more than 300 million barrels of storage capacity, deepwater docks, natural gas processing trains, fractionators, two propane dehydrogenation facilities and isobutane dehydrogenation facilities. The partnership stores and transports natural gas liquids (NGL), crude oil, natural gas, petrochemicals and refined products using its midstream assets. A large portion of its contracts are fee-based, with inflation protection provisions. Therefore, EPD likely generated stable cash flows in the September-end quarter of 2026.

For the third quarter, the Zacks Consensus Estimate for the NGL Pipelines and Services segment’s gross operating margin is $1,572 million, up from $1,369 million in the prior-year quarter. The estimate for the Crude Oil Pipelines and Services segment is pegged at $420 million compared with $377 million a year ago. However, the Natural Gas Pipelines & Services segment is expected to face pressure, with its gross operating margin estimated at $374 million, down from $402 million in the prior-year period.

Q3 Earnings Whispers for EPD StockOur proven model does not conclusively predict an earnings beat for EPD this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that is not the case here, as you will see below.

Enterprise Products' Earnings ESP: EPD has an Earnings ESP of -2.87%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank of EPD: Enterprise Products currently carries a Zacks Rank #2.

Stocks to ConsiderHere are some energy stocks that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.

ExxonMobil Holdings Corporation (XOM - Free Report) has an Earnings ESP of +6.03% and currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

XOM is scheduled to release third-quarter 2026 earnings on Oct. 30. The Zacks Consensus Estimate for XOM’s earnings is pegged at $3.90 per share, indicating a 107.5% improvement from the prior-year reported figure.

EOG Resources (EOG - Free Report) has an Earnings ESP of +0.79% and carries a Zacks Rank #2 at present. EOG is scheduled to release third-quarter 2026 earnings on Nov. 5.

The Zacks Consensus Estimate for EOG’s earnings is pegged at $4.45 per share, suggesting a 64.2% improvement from the prior-year reported figure.

BP plc (BP - Free Report) has an Earnings ESP of +7.13% and a Zacks Rank #1. BP is scheduled to release third-quarter 2026 earnings on Oct. 30.

The Zacks Consensus Estimate for BP’s earnings is pegged at $2.66 per share, suggesting a 212.9% increase from the prior-year reported figure.

As consumer habits shift, investors are weighing high-growth disruptors against established category leaders. Choosing between Dutch Bros (BROS +2.23%) and Lululemon Athletica (LULU +4.39%) requires balancing rapid expansion against proven profitability.

Dutch Bros is a drive-thru coffee specialist known for speed and community, while Lululemon is a dominant force in athletic apparel with a premium brand. While they operate in different industries, both compete for discretionary consumer spending and offer distinct risk-reward profiles for growth-oriented investors.

The case for Dutch BrosDutch Bros operates a rapidly expanding network of drive-thru coffee shops, primarily serving the consumer discretionary stocks category. The company focuses on high-speed service and community engagement through its signature brand.

Through the June quarter of fiscal 2026, trailing-12-month (TTM) revenue reached nearly $1.9 billion, which was a significant 29.6% increase over the previous year. This growth follows a strong multi-year trend of expansion from under $1 billion in revenue just three years ago.

Dutch Bros reported TTM net income of approximately $92 million. This represents a net margin of roughly 7%, showing a steady improvement from the nearly break-even levels seen in 2023.

As of its June 2026 balance sheet, the company reported a debt-to-equity ratio of approximately 1.2x. This metric compares total debt to shareholders' equity. The current ratio, which measures the company's ability to pay off short-term debts with short-term assets, was roughly 1.4x.

TTM free cash flow was approximately $95 million, calculated by subtracting capital expenditures from cash from operations.

The case for Lululemon AthleticaLululemon Athletica specializes in technical athletic apparel and accessories for a global customer base. The company operates more than 800 stores and a large digital platform across 30 countries. It serves guests through physical storefronts, mobile apps, and third-party marketplaces. The company also manages a "Like New" re-commerce program as part of its circular ecosystem, which allows guests to trade in and purchase used gear.

Through the August-ending quarter for fiscal 2027, TTM revenue reached $11 billion, reflecting a year-over-year growth rate of approximately 1.7%. This performance generated trailing net income of $1.4 billion. The resulting net margin was roughly 13%, which remains high for the apparel industry, though slightly lower than in previous years. Stable profitability allows the company to reinvest in international expansion and product innovation.

As of its August 2026 balance sheet, the company maintained a debt-to-equity ratio of nearly 0.4x. This low level of debt relative to equity suggests a conservative approach to financing. The current ratio was approximately 2.2x, indicating a strong buffer to meet immediate financial obligations.

TTM Free cash flow was roughly $1.3 million, representing the cash remaining after the company covers its operating expenses and capital investments.

Risk profile comparisonDutch Bros faces intense competition from established giants like Starbucks and other beverage chains. The company is heavily concentrated in the Western United States, which leaves it vulnerable to regional issues such as wildfires and localized economic downturns. It also relies on a concentrated supply chain for coffee beans and energy drink packaging.

Furthermore, Dutch Bros faces execution risks as it aggressively expands its footprint into new markets.

Lululemon Athletica is managing a significant leadership transition, including the upcoming appointment of a new chief executive officer. The company also faces public pressure and board challenges from its founder. Its supply chain is heavily concentrated in Vietnam and mainland China, exposing the business to geopolitical tensions and trade policy shifts.

Additionally, Lululemon must compete against established athletic brands like Nike and privately owned brands like Alo Yoga in a highly competitive athletic apparel industry.

Valuation comparisonLululemon offers a much lower entry price relative to its earnings and sales, whereas Dutch Bros carries a premium valuation tied to its high revenue growth. The P/S ratio compares market capitalization to sales over the past twelve months.

MetricDutch Broslululemon athleticaForward P/E43.6x10.8xP/S ratio4.2x1.1xValuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

Both businesses are operating in a crowded market for beverages and apparel. Lululemon is cheaper, but that reflects weakening growth and uncertainty as it transitions to new leadership. Even though Dutch Bros trades at a higher earnings multiple, I would rather buy Dutch Bros stock than Lululemon in 2026.

Dutch Bros is one of the most promising emerging restaurant growth stories right now. Its same-store sales have outperformed Starbucks' in recent years, indicating it is gaining a loyal customer base in the small number of states where it has a concentrated store presence. It operated 1,225 locations as of June 30, 2026, concentrated in the Western U.S.

Lululemon has the potential to offer greater upside over the next several years, as the stock trades at a low earnings multiple that may undervalue the brand. However, given the leadership change, I want to see more evidence of a working sales strategy before buying the stock.

Dutch Bros has shown more resilience in a challenging consumer spending environment. It posted a 5.8% year-over-year increase in same-shop sales last quarter. With company guidance pointing to 5%-6% same-shop growth for the full year, the recent dip looks like a good buying opportunity.

SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ.

Oral Presentation Details

Presentation Title: Inhibition of the KRAS oncoprotein sensitizes pancreatic cancer to NK cell immunotherapy
Abstract No.: 655
Presenter: Paarth Dodhiawala, University of Minnesota Medical School1
Presentation Date: Friday, November 6, 2026
Presentation Time: 3:05-3:20 PM MT
Location: North Building – 300 Level – Halls BC
Session 106a: Combination Therapies Involving Cell Therapy, 1:45-3:25 PM MST
Session Description: While cell therapy has transformed the treatment of certain hematologic malignancies, its impact in solid tumors remains limited by antigen heterogeneity, immunosuppressive microenvironments, and nutrient deprivation. As efforts to engineer more effective immune cells continue, there is growing interest in combining cell therapies with complementary approaches to enhance their function and engage endogenous immunity. This session will highlight diverse strategies to extend the clinical impact of cell therapies through rational combination approaches.
Session Schedule: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule#session-1596

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.

TriKE® is a registered trademark owned by GT Biopharma, Inc.

Investor Relations Contact:

LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
212-915-2577 

LinkedIn |Facebook |X |Instagram | YouTube

1 The University of Minnesota, pursuant to its license agreement with GT Biopharma, is entitled to receive royalties should commercial sales of product using the TriKE technology be realized, including GTB-3650 and GTB-5550. This interest has been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policies.